干扰素缺乏会导致严重的新冠病毒感染。 - Suppr

Suppr

超能文献

Interferon deficiency can lead to severe COVID.

作者信息

Meffre Eric, Iwasaki Akiko

出版信息

Nature. 2020 Nov;587(7834):374-376. doi: 10.1038/d41586-020-03070-1.

DOI:10.1038/d41586-020-03070-1

PMID:33139913

Abstract

摘要

相似文献

Interferon deficiency can lead to severe COVID.

Nature. 2020 Nov;587(7834):374-376. doi: 10.1038/d41586-020-03070-1.

The double edged interferon riddle in COVID-19 pathogenesis.

Crit Care. 2020 Nov 1;24(1):631. doi: 10.1186/s13054-020-03337-z.

Interferon-Induced Transmembrane Protein 3 Related to Coronavirus Disease 2019.

J Infect Dis. 2020 Sep 14;222(8):1413. doi: 10.1093/infdis/jiaa454.

Immune response in SARS-CoV-2 infection: the role of interferons type I and type III.

Braz J Infect Dis. 2020 Sep-Oct;24(5):428-433. doi: 10.1016/j.bjid.2020.07.011. Epub 2020 Aug 26.

The duration of SARS-CoV-2 shedding in patients recovering from COVID-19.

Epidemiol Mikrobiol Imunol. 2020 Summer;69(3):148-151.

[Analysis of coronavirus disease-19 (COVID-19) based on SARS autopsy].

Zhonghua Bing Li Xue Za Zhi. 2020 Apr 8;49(4):291-293. doi: 10.3760/cma.j.cn112151-20200211-00114.

Targeting the immunology of coronavirus disease-19: synchronization creates symphony.

Rheumatol Int. 2020 Aug;40(8):1343-1345. doi: 10.1007/s00296-020-04624-2. Epub 2020 Jun 12.

[Determination Methods of 2019 Novel Coronavirus (SARS-CoV-2)].

Zhongguo Yi Liao Qi Xie Za Zhi. 2020 Apr 8;44(4):359-362. doi: 10.3969/j.issn.1671-7104.2020.04.017.

Rhabdomyolysis as the main manifestation of coronavirus disease 2019.

Rheumatology (Oxford). 2020 Aug 1;59(8):2174-2176. doi: 10.1093/rheumatology/keaa351.

A race to determine what drives COVID-19 severity.

Nature. 2020 Jul;583(7816):366-368. doi: 10.1038/d41586-020-01915-3.

引用本文的文献

An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfection.

Microbiol Spectr. 2024 Jun 4;12(6):e0351623. doi: 10.1128/spectrum.03516-23. Epub 2024 Apr 30.

Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract.

Proc Natl Acad Sci U S A. 2024 Apr 30;121(18):e2319566121. doi: 10.1073/pnas.2319566121. Epub 2024 Apr 22.

Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response.

Life (Basel). 2023 Oct 26;13(11):2121. doi: 10.3390/life13112121.

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.

Sci Rep. 2023 Aug 7;13(1):12784. doi: 10.1038/s41598-023-39681-7.

Determinants of COVID-19 Disease Severity-Lessons from Primary and Secondary Immune Disorders including Cancer.

Int J Mol Sci. 2023 May 14;24(10):8746. doi: 10.3390/ijms24108746.

Distinct systemic immune networks define severe . mild COVID-19 in hematologic and solid cancer patients.

Front Immunol. 2023 Jan 9;13:1052104. doi: 10.3389/fimmu.2022.1052104. eCollection 2022.

SARS-CoV-2 spike protein induces a differential monocyte activation that may contribute to age bias in COVID-19 severity.

Sci Rep. 2022 Dec 2;12(1):20824. doi: 10.1038/s41598-022-25259-2.

Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients.

iScience. 2022 Dec 22;25(12):105608. doi: 10.1016/j.isci.2022.105608. Epub 2022 Nov 16.

Geographical distribution of host's specific SARS-CoV-2 mutations in the early phase of the COVID-19 pandemic.

Gene. 2023 Jan 30;851:147020. doi: 10.1016/j.gene.2022.147020. Epub 2022 Nov 4.

Pin-Pointing the Key Hubs in the IFN-γ Pathway Responding to SARS-CoV-2 Infection.

Viruses. 2022 Sep 30;14(10):2180. doi: 10.3390/v14102180.

本文引用的文献

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.

A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: letter to the editor.

J Endocrinol Invest. 2020 Aug;43(8):1175-1177. doi: 10.1007/s40618-020-01323-4. Epub 2020 Jun 9.

Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies.

Immunol Rev. 2019 Nov;292(1):90-101. doi: 10.1111/imr.12821. Epub 2019 Nov 12.

Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease.

Science. 2016 Apr 22;352(6284):463-6. doi: 10.1126/science.aaf3926.

A diverse range of gene products are effectors of the type I interferon antiviral response.

Nature. 2011 Apr 28;472(7344):481-5. doi: 10.1038/nature09907. Epub 2011 Apr 10.

Type I interferon inhibits interleukin-1 production and inflammasome activation.

Immunity. 2011 Feb 25;34(2):213-23. doi: 10.1016/j.immuni.2011.02.006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验